In silico design and analysis of crrna for post transcriptional regulation of oncogenic mir-128-2 and mir-217 by crispr-c2c2 technique.

Mahsa Bourbour,1,* Fatemeh ebrahimi tarki,2 Mahboobeh zarrabi,3

1. alzahra university,department of biotechnology, computational group
2. alzahra university,department of biotechnology,computational group
3. alzahra university, department of biotechnology,computational group

Abstract


Introduction

Based on recent studies some micrornas could have drug resistant effects in turmeric cells during therapy. there are evidences that mir-128 and mir-217 have been effected in lung cancer and breast cancer tumor drug resistance, respectively. recent studies have demonstrated that oncogenic mirnas are responsible for drug resistance by interfering with dna-repair pathway and apoptosis pathway. according to this, inhibition and reduction of micrornas expression, can have great effects on drug resistance. so in this article we are going to study the effect of microrna inhibition by genome editing technique, in drug resistance turmeric cells.

Methods

Crispr-c2c2 technique, have been revealed in 2017 by broad institute, can target these micornas precursors and makes post transcriptional regulation possible. in this method the c2c2 protein has a very crucial role. c2c2 has two rnase activities, one for cutting its rna target and the other for processing the crispr rna (crrna). functional studies revealed that c2c2 was an rna-guided rna-targeting crispr effector.

Results

In this article we design crrna for targeting mir-128 and mir-217 precursor by crispr rt, due to decreasing the transcript of them. after that we evaluate crrna structure and specificity. the best one was selected for expression inhibition of mir-128 and mir-217.

Conclusion

Designed crrna can targeted mir-128 and mir-217 with high specificity and makes post-transcriptional repression possible.so there is high probability for resolving drug resistance issue in tumors.

Keywords

Crispr-c2c2, oncogenic mirna, drug resistance, crrna, crispr-rt